WAT · Earnings call · 2026Q2T · Full report
Product Launch and Transition
WATERS CORP /DE/ · 2026-08-04 · Importance 31 · Surprise 42 · In source text
Waters launched the Cyclic IMS P20 and Xevo MRT P10 high-resolution mass spectrometers, targeting structural and spatial omics, multi-omics, speed and throughput. BioResolve Peptide and GTxResolve Lipid columns were introduced for GLP-1 peptides, insulin and nanoparticle separations, with twice the resolving power and sensitivity of competing products. The Xevo TQ Absolute XR IVD mass spectrometer adds five-times greater sensitivity and sixfold greater robustness for women’s health, cancer assessment and toxicology. Other important launches include the FACSDiscover A7 cell analyzer, BACTEC FXI blood culture system and Coin Cell Differential Scanning Calorimeter.
Key facts
- FACSDiscover A7 Cell Analyzer set to launch on September 15, 2026
- Launched two high-resolution mass spec products at ASMS: Cyclic IMS P20 and Xevo MRT P10
- Bioseparations launches: BioResolve Peptide and GTxResolve Lipid columns
- Launched Xevo TQ Absolute XR IVD mass spec, delivering 5x greater sensitivity and a sixfold increase in robustness
- Launched Onclarity HPV at-home testing solution (now launching) alongside BACTEC FXI
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | — | FACSDiscover A7 Cell Analyzer set to launch on September 15, 2026 |
| revenue | positive | probable | — | Launched two high-resolution mass spec products at ASMS: Cyclic IMS P20 and Xevo MRT P10 |
| revenue | positive | probable | — | Bioseparations launches: BioResolve Peptide and GTxResolve Lipid columns |
| revenue | positive | probable | — | Launched Xevo TQ Absolute XR IVD mass spec, delivering 5x greater sensitivity and a sixfold increase in robustness |
| revenue | positive | probable | — | Launched Onclarity HPV at-home testing solution (now launching) alongside BACTEC FXI |